Treatment Action Group Statement on BCG Vaccine and COVID-19
Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.
The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey
This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…
Treatment Action Group Statement on the HVTN 702 HIV Vaccine Trial Results
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.
2019 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.
Story: American Gene Technologies HIV Gene Therapy
November 2019 Examples of media coverage: Gene Tech Company Claims to Have Found a Cure for HIV/AIDS – NewNowNext, November 8, 2019 Researchers believe they’ve found the cure for HIV/AIDS – Pink News, November 8, 2019 Research Lab Believes They Have HIV/AIDS Cure – Instinct Magazine,…
Statement on U.S. FDA Report Highlighting Gaps in Pediatric Research
Treatment Action Group (TAG) welcomes a report released last week by the U.S. Food and Drug Administration (FDA) that highlights urgent gaps in pediatric research. This report confirms that we are missing critical information necessary to treat children affected by orphan diseases.
Story: HIV Eliminated from the Genomes of Living Animals
July 2019 Examples of media coverage: For the First Time, Researchers Eliminated HIV From the Genomes of Living Animals – TIME, July 2, 2019 Scientists eliminate HIV in the entire genome of lab mice for the first time ever: Breakthrough paves the…
Closing the Gap in Tuberculosis Research and Development Funding Briefs
In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.
A Pharma View on Delinkage and New Models for Biomedical Innovation: An Interview with Marc Destito from Otsuka Pharmaceutical
by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB…
Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research
By Richard Jefferys, Basic Science, Vaccines, and Cure Project Director, TAG The history of antiretroviral (ARV) drug development offers many examples of compounds that were originally discovered and investigated by publicly funded academic researchers, before being acquired and ushered to…